NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO.

NEW YORK, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo Nordisk" or "the Company") (NYSE:NVO) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Novo Nordisk securities between November 2, 2022 and December 19, 2024, both dates inclusive (the "Class Period").

NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Premier, Inc. ("Premier" or "the Company") (NASDAQ:PINC). Investors who purchased Premier securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PINC.

NEW YORK, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Owens & Minor, Inc. ("Owens & Minor" or "the Company") (NYSE:OMI). Investors who purchased Owens & Minor securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/OMI.

NEW YORK, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Construction Partners, Inc. ("Construction Partners" or "the Company") (NASDAQ:ROAD). Investors who purchased Construction Partners securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ROAD.

NEW YORK, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Direct Digital Holdings Inc. ("Direct Digital" or "the Company") (NASDAQ:DRCT). Investors who purchased Direct Digital securities prior to April 17, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/DRCT.

NEW YORK, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Venture Global, Inc. ("Venture Global" or "the Company") (NYSE:VG). Investors who purchased Venture Global securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/VG.

NEW YORK, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Eldorado Gold Corporation ("Eldorado" or "the Company") (NYSE:EGO). Investors who purchased Eldorado securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/EGO.

NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Evolv Technologies Holdings, Inc. ("Evolv Technologies" or "the Company") (NASDAQ:EVLV). Investors who purchased Evolv Technologies securities prior to August 19, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/EVLV.

NEW YORK, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Olin Corporation ("Olin" or "the Company") (NYSE:OLN). Investors who purchased Olin securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/OLN.

NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Equinix, Inc. ("Equinix" or "the Company") (NASDAQ:EQIX). Investors who purchased Equinix securities prior to May 3, 2019, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/EQIX.

NEW YORK, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Globe Life Inc. ("Globe Life" or "the Company") (NYSE:GL). Investors who purchased Globe Life securities prior to May 8, 2019, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/GL.

NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dominion Energy, Inc. ("Dominion" or "the Company") (NYSE:D). Investors who purchased Dominion securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/D.

NEW YORK, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of FMC Corporation ("FMC" or "the Company") (NYSE:FMC). Investors who purchased FMC securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FMC.

NEW YORK, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Allarity Therapeutics, Inc. ("Allarity" or "the Company") (NASDAQ:ALLR). Investors who purchased Allarity securities prior to May 17, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ALLR.

NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Huntington Ingalls Industries, Inc. ("Huntington Ingalls" or "the Company") (NYSE:HII). Investors who purchased Huntington Ingalls securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HII.

First Cohort B patient received 4 doses (approx. 819 million Gamma Delta T-cells) Cohort B recruitment continues at multiple clinical sites across the United Kingdom EDINBURGH, Scotland , Feb. 10, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced the first Cohort B patient in the ACHIEVE Phase 2B UK clinical trial, evaluating TCB008 in Acute Myeloid Leukemia, has completed the full dosing regiment.

MILWAUKEE , Feb. 10, 2025 /PRNewswire/ -- Johnson Controls (NYSE: JCI), the global leader for smart, healthy and sustainable buildings, has been named a top thermal management provider for data centers by ABI Research. The recognition highlights Johnson Controls' excellence in innovation and implementation, driven by its comprehensive product portfolio, global presence, and customer-centric approach to the data center thermal management industry.

NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Skyworks Solutions, Inc. ("Skyworks" or "the Company") (NASDAQ:SWKS). Investors who purchased Skyworks securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SWKS.

NEW YORK, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CARGO Therapeutics, Inc. ("CARGO" or "the Company") (NASDAQ:CRGX). Investors who purchased CARGO securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CRGX.